

Emerging-Trends: Executive Laser Report OPHTHALMIC AND MEDICAL LASER HIGHLIGHTS July 2013

Volume VIII No. 7

laser@emerging-trends.com

August 14, 2013

We hope that you are enjoying the summer. Subscribe to *Executive Laser Report* and get a free subscription to our sister publication, *Trends-in-Medicine*, as well as *Quick Takes*, our weekly news summary. You can even subscribe on our website: www.trends-in-medicine.com.

OPHTHALMIC LASER HIGHLIGHTS

Financial News

- **Abbott Laboratories** is buying **OptiMedica** for \$250 million, net of cash, plus additional payments totaling up to \$150 million.
- **Synergetics USA's** subsidiary, Synergetics Surgical EU, acquired M.I.S.S. Ophthalmics, a private ophthalmology distribution company incorporated in England and Wales, for \$2.8 million in net cash.
- **TearLab** plans to offer \$30 million worth of shares of its common stock in an underwritten public offering. TearLab also said that its preliminary financial estimates show that total revenue for the quarter ended June 30 will be in the range of \$3.4 million to \$3.6 million.

Other News

- **Ellex** launched its proprietary SLT technology in the US.
- **LCA-Vision** said that 12,994 procedures were performed in 2Q13 compared to 14,415 procedures in 2Q12.
- **Lumenis** will distribute Visionix's ophthalmic and optometric diagnostics product line in China.
- The FDA cleared **Topcon Medical Laser Systems'** Pascal Synthesis, a portable, dual-port pattern-scanning laser available in either 532 nm or 577 nm wavelengths.

MEDICAL/SURGICAL LASER HIGHLIGHTS

Financial News

- **AngioDynamics'** 4Q13 financial results (ended May 15) were mixed, with pro forma revenue down 2% compared to 4Q12, but losses narrowed.
- In an SEC filing, **Biolase** registered shares worth up to a maximum of \$30 million.

2731 N.E. Pinecrest Lakes Blvd.
Jensen Beach, FL 34957
772-334-7409 • Fax 772-334-0856
www.emerging-trends.com

Publisher: Stephen Snyder
Managing Editor: Michael Woods
Contributing Editor: D. Woods
Editor: Betty Teel

The information and opinions expressed in Executive Laser Report have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter. Copyright © 2013. This document may not be reproduced without written permission of the publisher.

- **MedX Health** issued 3,620,780 units – a total of 3,620,780 common shares – at a deemed value of \$0.10 per share, and 1,810,390 share purchase warrants, to settle outstanding debt of \$362,078.16.
- **Spectranetics'** financial results for 2Q13 and six months ended June 30 showed an increase in revenue.
- **Tria Beauty** closed \$45.5 million in new equity financing and a new structured debt facility.
- **Vascular Solutions'** 2Q13 results showed that net revenue increased 11% to a record quarterly level of \$27.4 million compared to \$24.7 million in 2Q12.

Other News

- **Biolase** has a strategic agreement with Valam Corporation to develop, market, and sell office-based laser systems to otolaryngologists.
- **CryoLife** received FDA premarket approval for its new Sologrip minimally-invasive laser fiber optic delivery system designed for use with the company's **Cardiogenesis** transmyocardial revascularization (TMR) system.
- **Guided Therapeutics** said that its LuViva advanced cervical scan is still under FDA review, despite the PMA application passing the 180 day internal guidance point.
- **Lutronic** said that the Infini is now available for sale in the US.
- Voce Capital Management delivered a letter to **Solta Medical's** board of directors demanding the formation of a special committee to evaluate a strategic sale or merger of the company.

